Clinical Trials Logo

Melanoma (Skin) clinical trials

View clinical trials related to Melanoma (Skin).

Filter by:

NCT ID: NCT03767348 Recruiting - Cancer Clinical Trials

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Start date: September 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

NCT ID: NCT03740503 Recruiting - Breast Cancer Clinical Trials

Genomic Investigation of Unusual Responders

GENIUS
Start date: November 1, 2013
Phase:
Study type: Observational

Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and/or other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.

NCT ID: NCT03643289 Recruiting - Melanoma (Skin) Clinical Trials

Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics

PRIMM
Start date: April 4, 2018
Phase:
Study type: Observational

This study will investigate the effects of gut microbiome diversity (richness in terms of many bacterial species in the gut) on responses and side effects of immunotherapy in advanced melanoma patients. Immunotherapy for melanoma is especially damaging for the gut with colitis which can lead to death and significant morbidity with repeated hospital admissions. The richness of the microbiome in the gut may be protective against colitis and other side effects but this needs to be confirmed. There is also some preliminary evidence that the gut microbiome diversity can enhance responses to immunotherapy in cancer but this has been shown in small numbers of melanoma patients.

NCT ID: NCT03621462 Not yet recruiting - Melanoma (Skin) Clinical Trials

Elucid Labs AIDA™ - Labelled Image Acquisition Protocol

Start date: October 15, 2018
Phase: N/A
Study type: Interventional

Diagnosis of melanoma involves physical examination of the lesion with many dermatologists adjunctively employing dermoscopes. The rate of misdiagnosis of melanoma remains significant, along with a high rate of referral to biopsy. Elucid Labs (Waterloo, Ontario) has developed a novel handheld, digital dermoscope with accompanying visualization and analysis software - the Artificial Intelligence Dermatology Assistant (AIDA™). Apart from collecting conventional demoscopic images, AIDA also collects images at various spectral bands. The aim of this study is to understand and quantify the value of this novel adjunctive information for dermatologists diagnosing atypical skin lesions.

NCT ID: NCT03620019 Recruiting - Melanoma Clinical Trials

Denosumab + Pembrolizumab in Patients With Stage IV Melanoma

Start date: September 25, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, phase II study designed to investigate the pharmacodynamic and antitumor effects of denosumab alone and in combination with pembrolizumab in patients with unresectable PD-1/PD-L1 inhibitor-naïve regional and distant metastatic melanoma (AJCC stage III/IV) by performing translational research on peripheral blood and tumor tissue collected before and during denosumab alone or with pembrolizumab treatment.

NCT ID: NCT03595683 Recruiting - Melanoma Clinical Trials

Pembrolizumab and EDP1503 in Advanced Melanoma

Start date: October 2, 2018
Phase: Phase 2
Study type: Interventional

This study is being done to determine if orally administered EDP1503 will enhance the response to standard immunotherapy treatment (pembrolizumab) in participants with advanced melanoma. The study will involve initial administration of EDP1503 for a run-in period (2 weeks) followed by administration of both EDP1503 (twice daily) and pembrolizumab (every 3 weeks). Mandatory biopsies are required before starting study treatment and after 2 weeks of EDP1503 dosing.

NCT ID: NCT03581188 Enrolling by invitation - Melanoma (Skin) Clinical Trials

A Research Study of Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.

MEL-SELF
Start date: July 30, 2018
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to evaluate digitally supported skin self-examination compared to usual care in people treated for localised melanoma. Patients may be eligible to join this study if they are aged 18 years or above, have been treated for stage 0/I/II melanoma and are attending regular melanoma surveillance follow-ups at the Melanoma Institute Australia (MIA), Royal Prince Alfred Hospital (RPAH) or the Newcastle Skin Check Clinic. People who are found to be eligible and who consent to participate will be randomised (allocated by chance) to the intervention or usual care in a 1:1 ratio. Usual care group will receive an educational booklet on early melanoma and the usual number of routine clinic visits. In addition to usual care, participants allocated to the intervention group will be required to download a skin checker App to their smartphone and will use a mobile dermatoscope to perform total body skin self-examinations every 2 months for 12 months in total. Email and SMS reminders will also be sent every two months to participants in the intervention group. Participants will be documented on how well they are able to perform a self skin examination, their levels of melanoma-related anxiety, the number of skin lesions biopsied or removed, and the costs of follow-up to the participant and to the healthcare system. Frequent follow-up of localised melanoma is time and resource intensive, and has not shown improved outcomes. This pilot study will provide evidence on which model is best for follow-up care after treatment for localised melanoma.

NCT ID: NCT03543969 Recruiting - Melanoma (Skin) Clinical Trials

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Start date: May 23, 2018
Phase: Early Phase 1
Study type: Interventional

This is a pilot study evaluating the feasibility of using adaptive intermittent dosing of vemurafenib and cobimetinib in BRAF mutant patients with elevated baseline lactate dehydrogenase (LDH). The purpose of this study is to determine whether an intermittent adaptive dosing of vemurafenib and cobimetinib may be superior to standard, continuous dosing with these study drugs.

NCT ID: NCT03535077 Recruiting - Melanoma (Skin) Clinical Trials

Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)

Start date: January 24, 2018
Phase:
Study type: Observational

The goal of the SFI is to provide non-invasive information about tissue remodeling occurring during melanocytic transition and atypia development in the skin

NCT ID: NCT03518229 Not yet recruiting - Melanoma (Skin) Clinical Trials

Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors

Start date: February 2019
Phase: N/A
Study type: Interventional

This project will pilot test whether a wearable device that tracks sun exposure and provides alerts regarding sun exposure and protection behaviors will reduce sunburns in melanoma survivors. The use of wearable technology devices has grown quickly over the last decade and studies using these devices to promote physical activity and weight loss have been promising. The investigators will pilot test the technology device versus a similar control device in 80 melanoma survivors and compare sunburns between the two groups after the three month intervention.